MedTrace Logo

Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer

NCT00002487 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-09-17

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Dipyridamole may increase the effectiveness of methotrexate and kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of combining methotrexate and dipyridamole in treating patients with advanced ovarian cancer that is recurrent after or refractory to cisplatin-based chemotherapy.

Conditions

Interventions

DRUG

dipyridamole

DRUG

methotrexate

Sponsors & Collaborators

  • Ottawa Regional Cancer Centre

    lead OTHER

Principal Investigators

  • Rakesh Goel, MD, FRCPC · Ottawa Regional Cancer Centre

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1991-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002487 on ClinicalTrials.gov